Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Aug 5;20(15):e912-e914.
doi: 10.4244/EIJ-E-24-00013.

Is bivalirudin ready for a comeback? Pros and cons

Gregg W Stone, Oludamilola Akinmolayemi, Rod H Stables
Editorial

Is bivalirudin ready for a comeback? Pros and cons

Gregg W Stone et al. EuroIntervention. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

R.H. Stables has no conflicts of interest to declare.

Figures

Figure 1
Figure 1. Adverse events up to 14 days, as observed in the bivalirudin arm of the HEAT-PPCI trial.
Some initial bleeding events are followed by ischaemic issues and vice versa. Mortality often follows another adverse event. A similar pattern is seen in the heparin arm. CVA: cerebrovascular accident; MI: myocardial infarction; Revasc: revascularisation
See this image and copyright information in PMC

References

    1. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218–30. - PubMed
    1. Li Y, Liang Z, Qin L, Wang M, Wang X, Zhang H, Liu Y, Li Y, Jia Z, Liu L, Zhang H, Luo J, Dong S, Guo J, Zhu H, Li S, Zheng H, Liu L, Wu Y, Zhong Y, Qiu M, Han Y, Stone GW. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. Lancet. 2022;400:1847–57. - PubMed
    1. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, Jüni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720–826. - PubMed
    1. Bikdeli B, Erlinge D, Valgimigli M, Kastrati A, Han Y, Steg PG, Stables RH, Mehran R, James SK, Frigoli E, Goldstein P, Li Y, Shahzad A, Schüpke S, Mehdipoor G, Chen S, Redfors B, Crowley A, Zhou Z, Stone GW. Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials. Circulation. 2023;148:1207–19. - PubMed
    1. Stone GW. . Bivalirudin Is the Most Evidence Based Antithrombin Agent for Primary PCI. Presented at TCT 2023: 23-26 October 2023, San Francisco, CA, USA; TCT 2023; 23-26 October 2023; San Francisco, CA, USA. Presented at TCT 2023: 23-26 October 2023, San Francisco, CA, USA.

Publication types

MeSH terms

LinkOut - more resources